Bengaluru: The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu. The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older. The company also submitted separate late-stage data ​showing the vaccine generated stronger antibody responses than Sanofi's high-dose flu ⁠vaccine in ‌adults 65 and older. Jefferies analysts had forecast $750 million in U.S. sales of Moderna's flu ​shot and combination ​COVID-flu vaccine by 2030. Former FDA Commissioner Marty Makary and former vaccine chief Vinay Prasad were forced to resign earlier this year amid controversies over vaccine and rare-disease drug reviews, including Moderna's flu vaccine application.